

1 ERCC1 mice, unlike other premature aging models, display accelerated epigenetic  
2 age

3

4 Kevin Perez<sup>1,2</sup>, Alberto Parras<sup>1,2</sup>, Cheyenne Rechsteiner<sup>1</sup>, Amin Haghani<sup>3</sup>, Robert Brooke<sup>4</sup>,  
5 Calida Mrabti<sup>1</sup>, Lucas Schonfeldt<sup>1</sup>, Steve Horvath<sup>3,4,5</sup>, Alejandro Ocampo<sup>1,10</sup>

6

7 <sup>1</sup>Department of Biomedical Sciences, Faculty of Biology and Medicine, University of  
8 Lausanne, Lausanne, Switzerland.

9 <sup>3</sup>Altos Labs, San Diego, USA

10 <sup>4</sup>Epigenetic Clock Development Foundation, Torrance, CA, USA

11 <sup>5</sup>Human Genetics, David Geffen School of Medicine, University of California, Los Angeles,  
12 USA

13

14 <sup>2</sup>These authors contributed equally.

15 <sup>10</sup>Lead contact.

16 Correspondence: alejandro.ocampo@unil.ch

17

18 **Keywords:** progeria, epigenetic clock, methylation, DNA damage, accelerated aging

19 **ABSTRACT**

20 Over the last decades, several premature aging mouse models have been developed to  
21 study aging and identify interventions that can delay age-related diseases. Yet, it is still  
22 unclear whether these models truly recapitulate natural aging. Here, we analyzed DNA  
23 methylation in multiple tissues of four previously reported mouse models of premature aging  
24 (ERCC1, LAKI, POLG and XPG). We estimated DNA methylation (DNAm) age of these  
25 samples using the Horvath clock. The most pronounced increase in DNAm age could be  
26 observed in ERCC1 mice, a strain which exhibits a deficit in DNA nucleotide excision repair.  
27 In line with these results, we detected an increase in epigenetic age in fibroblasts isolated  
28 from patients with progeroid syndromes associated with mutations in DNA excision repair  
29 genes. These findings highlight ERCC1 as a particularly attractive mouse model to study  
30 aging in mammals and suggest a strong connection between DNA damage and epigenetic  
31 dysregulation during aging.

32

33 **MAIN TEXT**

34 The world's population is growing older. Since aging represents the strongest risk factor for  
35 most human diseases, it is therefore key to identify anti-aging interventions that could delay  
36 or even reverse the aging process<sup>1</sup>. Towards this goal, several accelerated aging mouse  
37 models have been developed to study the aging process<sup>2,3</sup>, some of them stemming from  
38 existing human disorders<sup>4,5</sup>. In this line, premature aging rodents could speed up the  
39 discovery of anti-aging interventions by shortening the experimental time, but only if the  
40 results can be translatable to natural aging. Nevertheless, the physiological relevance of  
41 these models and whether they truly recapitulate or phenocopy natural aging remains  
42 controversial. Epigenetic changes are one of several hallmarks of aging in numerous  
43 organisms<sup>6</sup>. The importance of epigenetic changes in mammals has been reinforced by the  
44 development of epigenetic clocks that can accurately estimate age in multiple tissues and all  
45 mammalian species<sup>7-11</sup>. Interestingly, several anti-aging interventions have been shown to  
46 reverse these clocks<sup>12</sup>, including cellular reprogramming<sup>13-16</sup>. Here, we sought to assess the  
47 relevance of several premature aging mouse models to study aging. Toward this end, we  
48 analyzed mouse models of segmental progeria by assessing the epigenetic age of multiple  
49 tissues and organs using epigenetic clocks based on DNA methylation.

50

51 Specifically, we analyzed the epigenetic age ("Horvath Pan Tissue clock")<sup>17</sup> of five tissues of  
52 four commonly used premature aging models including: ERCC1, XPG, LAKI and POLG  
53 mice. These mouse strains cause premature aging through various biological mechanisms  
54 by carrying mutations that lead to the manipulation of different hallmarks of aging.  
55 Specifically, ERCC1<sup>18</sup> and XPG<sup>19</sup> mice exhibit a deficit in nucleotide excision repair (NER) of  
56 the nuclear DNA, POLG mice show accumulation of mitochondrial DNA mutations<sup>20,21</sup> and  
57 lastly LMNA knock-in (LAKI) mice suffer nuclear lamina defects<sup>22,23</sup>. To perform comparative  
58 studies in these strains, we assessed the DNA methylation age (DNAm) in ERCC1<sup>KO/Δ</sup>,  
59 XPG<sup>KO/KO</sup>, LAKI<sup>TG/TG</sup> and POLG<sup>TG/TG</sup> mice at several timepoints including during post-natal  
60 development, at median survival, and in old age, relative to each model's own lifespan. Both

61 proliferative (blood and skin) and more terminally differentiated tissues (liver, cerebral cortex,  
62 and skeletal muscle) were analyzed at these ages (Figure 1a). During the generation of  
63 experimental mice, we noticed that while LAKI<sup>TG/TG</sup> and POLG<sup>TG/TG</sup> mice were born at a  
64 predicted Mendelian frequency, ERCC1<sup>KO/Δ</sup> and XPG<sup>KO/KO</sup> showed a perinatal lethality  
65 (Figure S1a). Furthermore, as previously reported the four premature aging animals were  
66 significantly smaller and exhibited reduced body weight compared to their control littermates  
67 as expected (Figure 1b). Before analyzing the progeria models, we first looked at the clock  
68 performance in the control littermate WT mice (C57BL6J and C57BL6J|FVB hybrid  
69 backgrounds), a quality check that methylation can accurately predict chronological age in  
70 multiple tissues. The chronological age prediction in these two different backgrounds was  
71 highly accurate in blood (C57BL6J, RMSE: 2.08wk,  $r = 0.99$ ; C57BL6J|FVB, RMSE: 2.55wk,  
72  $r = 0.95$ ) and provided sufficient accuracy in the other tissues (Figure S1b and Table S1),  
73 confirming the precision of the DNAm clock to predict age, particularly in blood. Next, we  
74 determined the DNAm age in the five tissues of ERCC1<sup>KO/Δ</sup>, LAKI<sup>TG/TG</sup> and XPG<sup>KO/KO</sup> at 8  
75 weeks, and POLG<sup>TG/TG</sup> at 30 weeks of age corresponding to the relative median survival of  
76 the strain. Strikingly, ERCC1<sup>KO/Δ</sup> was the only premature aging model where we observed  
77 increased biological age compared to control littermates (Figure 1c). Importantly, the  
78 biological age of ERCC1<sup>KO/Δ</sup> mice was most increased in blood [WT: 6.85w (1.62), KO/Δ:  
79 12.46w (1.08)], but was also significantly increased in brain, liver, skeletal muscle and skin,  
80 tissues and organs known to be affected in this mouse model. Conversely, we did not detect  
81 any acceleration in DNAm age at 8 weeks in LAKI or XPG mice, nor in POLG mice at 30  
82 weeks in any tissue (Figure 1c). This result indicates that only ERCC1 aging mouse model  
83 shows a significant increase in epigenetic age at the median lifespan.

84

85 Subsequently, and with the goal of confirming this observation, we analyzed the methylation  
86 age at different times points during the lifespan of the mice including, ERCC1<sup>KO/Δ</sup> (2, 8 and  
87 20 weeks), LAKI<sup>TG/TG</sup> (8 and 23 weeks), and POLG<sup>TG/TG</sup> (30 and 47 weeks). Interestingly, in  
88 the ERCC1<sup>KO/Δ</sup> mice, biological age was increased mildly at 2 weeks old in blood, but not in

89 other tissues. However, at 20 weeks, DNAm age was significantly accelerated in blood, liver,  
90 and skin (Figure 2a and Table S2). Conversely, as we observed at earlier timepoints, DNAm  
91 age was not changed in any of the analyzed tissues at 14.4 weeks in LAKI<sup>TG/TG</sup> mice, nor in  
92 POLG<sup>TG/TG</sup> mice at 47 weeks (Figure S1c). Together, our results further confirm that the  
93 biological age measured by DNA methylation is increased only in the ERCC1 mouse model  
94 of premature aging, at multiple ages, with blood being the tissue with the strongest statistical  
95 power. Importantly, when the same analysis was restricted to either male or female only, the  
96 same trend appeared, with increased DNAm age primarily in the ERCC1 mouse model.  
97 Next, we wondered whether the observed differences between methylation age and  
98 chronological age in ERCC1 mice were constant or changed throughout life. To determine  
99 this accelerated aging rate, we calculated the slope between biological and chronological  
100 age in each tissue in ERCC1 +/+ vs. KO/Δ mice. Importantly, the rate was significantly  
101 different in blood (Slope: WT = 0.78, KO/Δ = 1.29), skeletal muscle (Slope: WT = 0.84, KO/Δ  
102 = 1.17) and brain (Slope: WT = 0.91, KO/Δ = 1.2) (Figure 2b), demonstrating that the  
103 difference between biological and chronological age increased during life in ERCC1<sup>KO/Δ</sup>  
104 mice.

105

106 Lastly, to investigate the potential relevance of these findings to human patients, we  
107 analyzed the DNAm age of samples obtained from patients affected by diseases caused by  
108 mutations in DNA excision repair genes associated with aging phenotypes: Xeroderma  
109 Pigmentosum (XP) affecting *ERCC5*<sup>24</sup>, and Cockayne Syndrome (CS) type A (CSA)  
110 affecting *ERCC8* and type B (CSB) affecting *ERCC6*<sup>25</sup>. Towards this goal, we profiled DNAm  
111 age from fibroblasts derived from patients at multiple ages: control (1, 5, 11-year-old), CSA  
112 (1, 3, 5-year-old), CSB (3, 8, 10-year-old), XP (1, 2, 5-year-old). For this analysis only, we  
113 selected the DNAm age from the “Skin&Blood” Clock, as this has previously been shown to  
114 be more accurate than the “PanTissue” clock to assess age of human fibroblasts<sup>26</sup>, a finding  
115 that we also confirmed in our own dataset (Figure 3a). Importantly, the DNAm age was  
116 significantly higher in the affected patients compared to control samples (Figure 3a). Finally,

117 we calculated the difference between DNAm age and chronological age for each sample,  
118 detecting a significant increase for the XP patients and a strong tendency in the rest of the  
119 disease samples (Figure 3b). Overall, these results indicate that human progeroid  
120 syndromes associated with mutations in DNA excision repair genes display accelerated  
121 epigenetic age.

122

123 Although premature aging models have been widely used to study aging and evaluate anti-  
124 aging interventions, their physiological relevance for the study of aging has not been deeply  
125 investigated. Here, we analyzed the biological age ("Horvath clock") of four premature aging  
126 mouse models (ERCC1, POLG, XPG, LAKI) and demonstrated that only ERCC1 mice truly  
127 shows accelerated aging.

128

129 Depletion of ERCC1 protein results in a defect in DNA repair, leading to an accumulation of  
130 DNA mutations in multiple tissues and organs. Importantly, DNA damage has been  
131 proposed as one of the most central hallmarks of aging, as well as a causative driver<sup>27,28</sup>.  
132 Here, we show that a defective DNA repair mechanism leads to epigenetic aging, strongly  
133 suggesting a link between DNA damage and epigenetic dysregulation. Interestingly, dietary  
134 restriction, the most robust anti-aging intervention, dramatically extends lifespan of  
135 ERCC1<sup>KO/Δ</sup> mice<sup>29</sup> and knocking down of *ERCC1* gene in blood specifically causes  
136 premature aging<sup>30</sup>. Furthermore, we noted that even though DNAm age was increased in  
137 ERCC1 mice already at 2 weeks, greater changes were observed in older animals indicating  
138 a progressive age acceleration during aging. In this line, we postulate that a higher DNA  
139 repair capacity during development<sup>31</sup> or embryonic reprogramming programs, which might  
140 prevent potential epigenetic dysregulation as consequence of DNA damage, could protect  
141 the animals during gestation. Taken together, these results suggest that ERCC1 mice stand  
142 perhaps as one of the most relevant mouse models of premature aging.

143

144 The methylation clock was more accurate in blood, a rapidly proliferative tissue that  
145 undergoes constant regeneration, in which the most significant and strongest differences  
146 between ERCC1 and control mice were observed. Therefore, due to its easy collection and  
147 strong sensitivity for epigenetic aging, we propose the use of blood as one of the best  
148 choices to study and analyze the effect of anti-aging interventions. Lastly, although multiple  
149 groups have examined the biological age of human diseases associated with premature  
150 aging, no changes in DNAm age have been observed in the blood of Hutchinson-Gilford  
151 progeria syndrome patients<sup>32</sup>. On the other hand, a significant increase in biological age was  
152 seen in samples from Werner<sup>33</sup>, Down syndrome even in newborns<sup>34</sup> in several human  
153 overgrowth syndromes including Sotos syndrome<sup>35</sup> and Tatton-Brown-Rahman syndrome<sup>36</sup>  
154 and very recently in Leigh Syndrome and mitochondrial encephalopathy with lactic acidosis  
155 and stroke-like episodes (MELAS) patients<sup>37</sup>. Other studies have identified changes in  
156 DNAm in premature aging models, independent of the DNA methylation clocks<sup>38-40</sup>. Our  
157 survey of mouse models of premature aging may be expanded to alternative premature  
158 aging models<sup>2</sup>, or additional tissues and timepoints. Likewise, it would be interesting to also  
159 assess biological age using newly developed clocks, such as transcriptomic, proteomic or  
160 chromatin accessibility clocks<sup>41-43</sup>.

161

## 162 **ACKNOWLEDGMENTS**

163 We would like to thank all members of the Ocampo laboratory for helpful discussions. We  
164 would like to thank the teams of mouse facilities at the University of Lausanne including  
165 Francis Derouet and Lisa Arlandi (animal facility at Epalinges), and Laurent Lecomte (animal  
166 facility of the Department of Biomedical Sciences) and colleagues. We thank Prof. Jan  
167 Hoeijmakers and Prof. Ingrid van der Pluijm for providing us the ERCC1 and XPG mice, and  
168 Prof. Carlos Lopez Otin and Prof. Andrea Ablasser for providing us the LAKI mice.  
169 This work was supported the Swiss National Science Foundation (SNSF), the University of  
170 Lausanne, and the Canton Vaud.

171

172 **CONFLICT OF INTEREST**

173 S.H. is a founder of the non-profit Epigenetic Clock Development Foundation which licenses  
174 several patents from his former employer UC Regents. These patents list S.H. as inventor.  
175 The other authors declare no conflicts of interest.

176

177 **AUTHOR CONTRIBUTIONS**

178 K.P. performed data and statistical analysis. A.P. generated mouse strains and collected  
179 tissues. C.M and L.S. were involved in culture and DNA extraction from human cells. C.R.  
180 extracted DNA from mice. S.H., A.H. analyzed data and made a critically revision. A.O.  
181 directed, supervised the study, designed the experiments, and reviewed the manuscript.  
182 K.P. and A.P generated the figures and wrote the manuscript with input from all authors.

183

184 **DATA AVAILABILITY STATEMENT**

185 The data supporting the findings of this study are available from the corresponding author  
186 upon reasonable request.

187 The mammalian methylation array is available from the nonprofit Epigenetic Clock  
188 Development Foundation (<https://clockfoundation.org/>)

189

190

191 **FIGURE LEGENDS**

192 **FIGURE 1. DNA methylation in premature aging mouse models. (a)** Schematic  
193 representation of premature mouse strains and littermate controls, tissues collected, and  
194 timepoints taken. **(b)** Evolution of body weight (grams) of mutant and controls mice from 4  
195 weeks until the euthanize point, data are mean  $\pm$  SEM. **(c)** Methylation biological age (in  
196 weeks) of ERCC1<sup>KO/Δ</sup>, XPG<sup>KO/KO</sup>, LAKI<sup>TG/TG</sup> at 8 weeks and POLG<sup>TG/TG</sup> at 30 weeks. Data  
197 are represented as box plots (center line shows median, box shows 25th and 75th  
198 percentiles and whiskers show minimum and maximum values and statistical significance  
199 was assessed by two-sided unpaired t-test.

200

201 **FIGURE 2. DNA methylation ERCC1 mice. (a)** Methylation biological age (in weeks) of  
202 ERCC1<sup>KO/Δ</sup> mice at 2, 8 and 20 weeks in multiple organs/tissues and WT littermate controls  
203 estimated by Horvath clock. Data are represented as box plots (center line shows median,  
204 box shows 25th and 75th percentiles and whiskers show minimum and maximum values and  
205 statistical significance was assessed by two-sided unpaired t-test. **(b)** Slope of aging in  
206 ERCC1<sup>KO/Δ</sup> and controls mice in tissues analyzed from 2 to 20 weeks old. Significance of the  
207 interaction term in the linear regression was analyzed.

208

209 **FIGURE 3. DNA methylation in fibroblasts from human premature aging diseases. (a)**  
210 DNAm age versus chronological age (in years) and **(b)** difference between biological and  
211 chronological age in human samples in fibroblasts isolated from individual with Cockayne  
212 Syndrome A (CSA), Cockayne Syndrome B (CSB), Xeroderma Pigmentosum (XP) and  
213 controls analyzed by Skin&Blood Clock. Data are represented as box plots (center line  
214 shows median, box shows 25th and 75th percentiles and whiskers show minimum and  
215 maximum values and statistical significance was assessed by two-sided unpaired t-test.

216

217 **SUPPLEMENTARY FIGURE 1. DNA methylation in premature aging mouse models**  
218 **additional data. (a)** Breeding protocol to generate the four premature mouse strains and  
219 littermate control mice. Statistical significance was assessed by Pearson's chi-squared test.  
220 **(b)** Correlation between biological and chronological age (in weeks) in WT control mice in  
221 C57BL6J and C57BL6J|FVB backgrounds in analyzed tissues from 2- to 47-week-old. **(c)**  
222 Methylation biological age of POLG<sup>TG/TG</sup> (at 30 and 47 weeks old) and LAKI<sup>TG/TG</sup> (at 8 and 23  
223 weeks) in multiple organs/tissues and WT littermate controls by Horvath clock. Data are  
224 represented as box plots (center line shows median, box shows 25th and 75th percentiles  
225 and whiskers show minimum and maximum values) and statistical significance was  
226 assessed by two-sided unpaired t-test.

227

228 **EXPERIMENTAL PROCEDURES**

229 **Animal housing**

230 All the experimental experiment were performed in accordance with Swiss legislation after  
231 the approval from the local authorities (Cantonal veterinary office, Canton de Vaud,  
232 Switzerland). Mice were housed in groups of five per cage with a 12hr light/dark cycle  
233 between 06:00 and 18:00 in a temperature-controlled environment at 25°C and humidity  
234 between 40 % and 70 %, with free access to water and food. Wild type (WT) and premature  
235 aging mouse models used in this study were generated by breeding (Figure S1a) and  
236 housed together until they reached the desired age in the Animal Facilities of Epalinges and  
237 Department of Biomedical Science of the University of Lausanne.

238

239 **Mouse strains**

240 ERCC1<sup>KO/Δ</sup><sup>44</sup> and XPG<sup>KO/KO</sup> mice<sup>19</sup> and littermate controls (ERCC1<sup>+/+</sup> and XPG<sup>+/+</sup>) were used  
241 in C57BL6J|FVB hybrid background. POLG<sup>D257A/D257A</sup>, herein referred to as POLG<sup>TG/TG</sup><sup>20,21</sup>  
242 and LAKI<sup>TG/TG</sup><sup>22</sup> and sibling controls (POLG<sup>+/+</sup> and LAKI<sup>+/+</sup>) were generated in C57BL6J  
243 background.

244

245 **Mouse monitoring and euthanasia**

246 All mice were monitored at least three times per week to evaluate their activity, posture,  
247 alertness, body weight, presence of tumors or wound, and surface temperature. Males and  
248 females were euthanized at the specific timepoints by CO<sub>2</sub> inhalation (6 min, flow rate 20%  
249 volume/min). Subsequently, before perfusing the mice with saline, blood was collected from  
250 the heart. Finally, multiple organs and tissues were collected in liquid nitrogen and used for  
251 DNA extraction to perform MethylArray.

252

253 **Cell culture and maintenance**

254 Human fibroblasts were obtained from the Coriell cell repositories and cultured in DMEM  
255 (Gibco, 11960085) with 10% FBS (Hyclone, SH30088.03) containing non-essential amino

256 acids, GlutaMax and Sodium Pyruvate (Gibco, 11140035, 35050061, 11360039) at 37°C in  
257 hypoxic conditions (3% O<sub>2</sub>). Subsequently, fibroblasts were passaged and cultured  
258 according to standard protocols.

259

260 **DNA extractions**

261 Total DNA was extracted from tissues and cells using Monarch Genomic DNA Purification  
262 Kit (New England Biolab, T3010L) and protocols were carefully followed. Tissues were cut  
263 into small pieces to ensure rapid lysis. Total DNA concentrations were determined using the  
264 Qubit DNA BR Assay Kit (Thermofisher, Q10211).

265

266 **DNA methylation clock**

267 The mouse clock was developed in<sup>17</sup>. We used the “Pan Tissue” mouse clock since we  
268 analyzed different tissues. The software code of the mouse clocks can be found in the  
269 supplements of<sup>17</sup>.

270 The mouse methylation data were generated on the small and the extended version of  
271 HorvathMammalMethylChip<sup>45</sup>. We used the SeSaMe normalization method<sup>46</sup>. Human  
272 methylation data were generated on the Illumina EPIC array platforms that profiles 866k  
273 cytosines. We used the noob normalization method implemented in the R function  
274 preprocessNoob. The human DNAm age was estimated using the Skin&blood clock  
275 algorithm<sup>26</sup>.

276

277 **Statistical analysis**

278 Unsupervised hierarchical clustering based on interarray correlation coefficients was used to  
279 identify putative technical outliers. One liver sample with negative methylation age was  
280 removed. All plots were generated using the R software package ggplot2. Statistical  
281 differences between groups were assessed using a two-tailed unpaired Student's t-test.  
282 Clock performance was assessed by correlation (Pearson coefficient) and Random Mean  
283 Square Error (RMSE), using the R software. To determine if there was a significant

284 difference in the slope of aging between WT and transgenic mice, we looked at the  
285 significance of the interaction term in the linear regression: DNAm age ~ WT/TG + Age +  
286 WT/TG\*Age.

287

## 288 REFERENCES

- 289 1 Partridge, L., Deelen, J. & Slagboom, P. E. Facing up to the global challenges of  
290 ageing. *Nature* **561**, 45-56, doi:10.1038/s41586-018-0457-8 (2018).
- 291 2 Koks, S. *et al.* Mouse models of ageing and their relevance to disease. *Mech Ageing  
292 Dev* **160**, 41-53, doi:10.1016/j.mad.2016.10.001 (2016).
- 293 3 Liao, C. Y. & Kennedy, B. K. Mouse models and aging: longevity and progeria. *Curr  
294 Top Dev Biol* **109**, 249-285, doi:10.1016/B978-0-12-397920-9.00003-2 (2014).
- 295 4 Bohr, V. A. Human premature aging syndromes and genomic instability. *Mech  
296 Ageing Dev* **123**, 987-993, doi:10.1016/s0047-6374(02)00039-8 (2002).
- 297 5 Brosh, R. M., Jr. & Bohr, V. A. Human premature aging, DNA repair and RecQ  
298 helicases. *Nucleic Acids Res* **35**, 7527-7544, doi:10.1093/nar/gkm1008 (2007).
- 299 6 Lopez-Otin, C., Blasco, M. A., Partridge, L., Serrano, M. & Kroemer, G. The  
300 hallmarks of aging. *Cell* **153**, 1194-1217, doi:10.1016/j.cell.2013.05.039 (2013).
- 301 7 Horvath, S. DNA methylation age of human tissues and cell types. *Genome Biol* **14**,  
302 R115, doi:10.1186/gb-2013-14-10-r115 (2013).
- 303 8 Simpson, D. J. & Chandra, T. Epigenetic age prediction. *Aging Cell* **20**, e13452,  
304 doi:10.1111/ace.13452 (2021).
- 305 9 Ake Lu, V. P., Fei, Z., Raj, K. & Horvath, S. Universal DNA Methylation Age Across  
306 Mammalian Tissues. *Innovation in Aging* **5**, 410-410,  
307 doi:10.1093/geroni/igab046.1588 (2021).
- 308 10 Bell, C. G. *et al.* DNA methylation aging clocks: challenges and recommendations.  
309 *Genome Biol* **20**, 249, doi:10.1186/s13059-019-1824-y (2019).
- 310 11 Bergsma, T. & Rogaeva, E. DNA Methylation Clocks and Their Predictive Capacity  
311 for Aging Phenotypes and Healthspan. *Neurosci Insights* **15**, 2633105520942221,  
312 doi:10.1177/2633105520942221 (2020).
- 313 12 Field, A. E. *et al.* DNA Methylation Clocks in Aging: Categories, Causes, and  
314 Consequences. *Mol Cell* **71**, 882-895, doi:10.1016/j.molcel.2018.08.008 (2018).
- 315 13 Simpson, D. J., Olova, N. N. & Chandra, T. Cellular reprogramming and epigenetic  
316 rejuvenation. *Clin Epigenetics* **13**, 170, doi:10.1186/s13148-021-01158-7 (2021).

317 14 Sarkar, T. J. *et al.* Transient non-integrative expression of nuclear reprogramming  
318 factors promotes multifaceted amelioration of aging in human cells. *Nat Commun* **11**,  
319 1545, doi:10.1038/s41467-020-15174-3 (2020).

320 15 Browder, K. C. *et al.* In vivo partial reprogramming alters age-associated molecular  
321 changes during physiological aging in mice. *Nature Aging*, doi:10.1038/s43587-022-  
322 00183-2 (2022).

323 16 Lu, Y. *et al.* Reprogramming to recover youthful epigenetic information and restore  
324 vision. *Nature* **588**, 124-129, doi:10.1038/s41586-020-2975-4 (2020).

325 17 Mozhui, K. *et al.* Genetic loci and metabolic states associated with murine epigenetic  
326 aging. *eLife* **11**, doi:10.7554/eLife.75244 (2022).

327 18 Weeda, G. *et al.* Disruption of mouse ERCC1 results in a novel repair syndrome with  
328 growth failure, nuclear abnormalities and senescence. *Curr Biol* **7**, 427-439,  
329 doi:10.1016/s0960-9822(06)00190-4 (1997).

330 19 Barnhoorn, S. *et al.* Cell-autonomous progeroid changes in conditional mouse  
331 models for repair endonuclease XPG deficiency. *PLoS Genet* **10**, e1004686,  
332 doi:10.1371/journal.pgen.1004686 (2014).

333 20 Kujoth, G. C. *et al.* Mitochondrial DNA mutations, oxidative stress, and apoptosis in  
334 mammalian aging. *Science* **309**, 481-484, doi:10.1126/science.1112125 (2005).

335 21 Trifunovic, A. *et al.* Premature ageing in mice expressing defective mitochondrial  
336 DNA polymerase. *Nature* **429**, 417-423, doi:10.1038/nature02517 (2004).

337 22 Osorio, F. G. *et al.* Splicing-directed therapy in a new mouse model of human  
338 accelerated aging. *Sci Transl Med* **3**, 106ra107, doi:10.1126/scitranslmed.3002847  
339 (2011).

340 23 Varga, R. *et al.* Progressive vascular smooth muscle cell defects in a mouse model  
341 of Hutchinson-Gilford progeria syndrome. *Proc Natl Acad Sci U S A* **103**, 3250-3255,  
342 doi:10.1073/pnas.0600012103 (2006).

343 24 Rizza, E. R. H. *et al.* Xeroderma Pigmentosum: A Model for Human Premature  
344 Aging. *J Invest Dermatol* **141**, 976-984, doi:10.1016/j.jid.2020.11.012 (2021).

345 25 Laugel, V. in *GeneReviews(R)* (eds M. P. Adam *et al.*) (1993).

346 26 Horvath, S. *et al.* Epigenetic clock for skin and blood cells applied to Hutchinson  
347 Gilford Progeria Syndrome and ex vivo studies. *Aging (Albany NY)* **10**, 1758-1775,  
348 doi:10.18632/aging.101508 (2018).

349 27 Yousefzadeh, M. *et al.* DNA damage-how and why we age? *eLife* **10**,  
350 doi:10.7554/eLife.62852 (2021).

351 28 Schumacher, B., Pothof, J., Vijg, J. & Hoeijmakers, J. H. J. The central role of DNA  
352 damage in the ageing process. *Nature* **592**, 695-703, doi:10.1038/s41586-021-  
353 03307-7 (2021).

354 29 Vermeij, W. P. *et al.* Restricted diet delays accelerated ageing and genomic stress in  
355 DNA-repair-deficient mice. *Nature* **537**, 427-431, doi:10.1038/nature19329 (2016).

356 30 Yousefzadeh, M. J. *et al.* An aged immune system drives senescence and ageing of  
357 solid organs. *Nature* **594**, 100-105, doi:10.1038/s41586-021-03547-7 (2021).

358 31 Mitchell, D. L. & Hartman, P. S. The regulation of DNA repair during development.  
359 *Bioessays* **12**, 74-79, doi:10.1002/bies.950120205 (1990).

360 32 Bejaoui, Y. *et al.* DNA methylation signatures in Blood DNA of Hutchinson-Gilford  
361 Progeria syndrome. *Aging Cell* **21**, e13555, doi:10.1111/acel.13555 (2022).

362 33 Maierhofer, A. *et al.* Accelerated epigenetic aging in Werner syndrome. *Aging*  
363 (*Albany NY*) **9**, 1143-1152, doi:10.18632/aging.101217 (2017).

364 34 Xu, K. *et al.* Accelerated epigenetic aging in newborns with Down syndrome. *Aging*  
365 *Cell* **21**, e13652, doi:10.1111/acel.13652 (2022).

366 35 Martin-Herranz, D. E. *et al.* Screening for genes that accelerate the epigenetic aging  
367 clock in humans reveals a role for the H3K36 methyltransferase NSD1. *Genome Biol*  
368 **20**, 146, doi:10.1186/s13059-019-1753-9 (2019).

369 36 Jeffries, A. R. *et al.* Growth disrupting mutations in epigenetic regulatory molecules  
370 are associated with abnormalities of epigenetic aging. *Genome Res* **29**, 1057-1066,  
371 doi:10.1101/gr.243584.118 (2019).

372 37 Yu, T. *et al.* Premature aging is associated with higher levels of 8-oxoguanine and  
373 increased DNA damage in the Polg mutator mouse. *Aging Cell* **21**, e13669,  
374 doi:10.1111/acel.13669 (2022).

375 38 Guastafierro, T. *et al.* Genome-wide DNA methylation analysis in blood cells from  
376 patients with Werner syndrome. *Clin Epigenetics* **9**, 92, doi:10.1186/s13148-017-  
377 0389-4 (2017).

378 39 Heyn, H., Moran, S. & Esteller, M. Aberrant DNA methylation profiles in the  
379 premature aging disorders Hutchinson-Gilford Progeria and Werner syndrome.  
380 *Epigenetics* **8**, 28-33, doi:10.4161/epi.23366 (2013).

381 40 Crochemore, C. *et al.* Epigenomic signature of the progeroid Cockayne syndrome  
382 exposes distinct and common features with physiological ageing. *bioRxiv*,  
383 2021.2005.2023.445308, doi:10.1101/2021.05.23.445308 (2021).

384 41 Meyer, D. H. & Schumacher, B. BiT age: A transcriptome-based aging clock near the  
385 theoretical limit of accuracy. *Aging Cell* **20**, e13320, doi:10.1111/acel.13320 (2021).

386 42 Lehallier, B., Shokhirev, M. N., Wyss-Coray, T. & Johnson, A. A. Data mining of  
387 human plasma proteins generates a multitude of highly predictive aging clocks that  
388 reflect different aspects of aging. *Aging Cell* **19**, e13256, doi:10.1111/acel.13256  
389 (2020).

390 43 Rechsteiner, C. *et al.* Development of a novel aging clock based on chromatin  
391 accessibility. *bioRxiv*, 2022.2008.2011.502778, doi:10.1101/2022.08.11.502778  
392 (2022).

393 44 de Waard, M. C. *et al.* Age-related motor neuron degeneration in DNA repair-  
394 deficient Ercc1 mice. *Acta Neuropathol* **120**, 461-475, doi:10.1007/s00401-010-0715-  
395 9 (2010).


396 45 Arneson, A. *et al.* A mammalian methylation array for profiling methylation levels at  
397 conserved sequences. *Nat Commun* **13**, 783, doi:10.1038/s41467-022-28355-z  
398 (2022).

399 46 Zhou, W., Triche, T. J., Jr., Laird, P. W. & Shen, H. SeSAMe: reducing artifactual  
400 detection of DNA methylation by Infinium BeadChips in genomic deletions. *Nucleic  
401 Acids Res* **46**, e123, doi:10.1093/nar/gky691 (2018).

402

## Aging mouse models

bioRxiv preprint doi: <https://doi.org/10.1101/2022.12.28.522011>; this version posted December 29, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license.




**Figure 1**

## ERCC1 mice

bioRxiv preprint doi: <https://doi.org/10.1101/2022.12.28.522011>; this version posted December 29, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license.

(a)



(b)





Figure 2


## Human patients

bioRxiv preprint doi: <https://doi.org/10.1101/2022.12.28.522011>; this version posted December 29, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license.




(a)



(b)



**Figure 3**



**Figure S1**

bioRxiv preprint doi: <https://doi.org/10.1101/2022.12.28.522041>; this version posted December 29, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license.

Tissue	C57BL6J [RMSE (r)]	C57BL6J   FVB [RMSE (r)]
<b>Brain</b>	8.74 (0.96)	4.18 (0.98)
<b>Liver</b>	8.49 (0.98)	3.04 (0.97)
<b>Muscle</b>	11.2 (0.98)	2.51 (0.95)
<b>Skin</b>	7.59 (0.96)	3.21 (0.91)

**Table S1**

Model	Timepoint	Tissue	WT [Avg (Sd; N)]	KO [Avg (Sd; N)]	P (t-test)	Sig
bioRxiv preprint doi: <a href="https://doi.org/10.1101/2022.12.28.522010">https://doi.org/10.1101/2022.12.28.522010</a> ; this version posted December 29, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license.						
ERCC1	2w	Brain	3.37 (1.54; 8)	3.12 (0.84; 8)	0.69	
		Liver	4.05 (0.9; 8)	4.89 (0.92; 7)	0.098	
		Muscle	3.86 (0.88; 8)	4.75 (1.33; 8)	0.138	
		Skin	4.33 (1.25; 8)	4.91 (1.25; 8)	0.368	
	8w	Blood	6.85 (1.62; 8)	12.46 (1.08; 8)	0	***
		Brain	12.8 (1.29; 8)	15.01 (1.84; 8)	0.016	*
		Liver	11.66 (1.33; 8)	14.78 (1.49; 8)	0.001	**
		Muscle	9.98 (1.23; 8)	11.87 (1.1; 8)	0.006	**
	20w	Skin	9.68 (1.36; 8)	11 (1.06; 8)	0.049	*
		Blood	16.95 (2.95; 10)	27.58 (3.83; 6)	0	***
		Brain	20.7 (4.23; 10)	25.39 (2.54; 6)	0.015	*
		Liver	21.56 (1.74; 9)	25.07 (3.62; 6)	0.065	
XPG	8w	Muscle	19.2 (2.95; 10)	25.82 (3.69; 6)	0.005	**
		Skin	15.97 (3.04; 10)	18.91 (2.37; 6)	0.051	
		Blood	7.96 (0.73; 8)	9.09 (1.08; 8)	0.03	*
		Brain	12.3 (2.4; 8)	13.67 (1.58; 8)	0.201	
		Liver	11.11 (1.83; 8)	11.45 (1.54; 8)	0.702	
LAKI	8w	Muscle	10.01 (1.8; 8)	10.07 (2.04; 8)	0.947	
		Skin	8.79 (1.14; 8)	8.18 (0.7; 8)	0.22	
		Blood	9.35 (0.42; 8)	8.44 (1.09; 8)	0.054	
		Brain	14.17 (1.74; 8)	14.46 (1.78; 8)	0.745	
		Liver	11.74 (1.34; 8)	10.59 (1.15; 8)	0.086	
	23w	Muscle	11.66 (0.81; 8)	10.94 (0.74; 8)	0.085	
		Skin	9.24 (1.24; 8)	8.55 (0.69; 8)	0.199	
		Brain	19.87 (NA; 1)	21.27 (3.54; 4)		
		Liver	21.13 (6; 2)	16.97 (2.31; 4)	0.501	
		Muscle	22.78 (4.04; 2)	17.92 (3.91; 3)	0.303	
POLG	30w	Skin	17 (3.36; 2)	15.92 (2.2; 4)	0.733	
		Blood	30.6 (2.68; 8)	27.3 (4.99; 8)	0.129	
		Brain	40.89 (2.93; 8)	37.5 (4.76; 8)	0.113	
		Liver	36.81 (2.15; 8)	35.63 (2.44; 8)	0.322	
		Muscle	41.67 (5.64; 8)	45.81 (5.36; 8)	0.154	
	47w	Skin	35.6 (7.44; 8)	34.05 (8.42; 8)	0.702	
		Brain	46.62 (7.83; 2)	45.96 (6.12; 2)	0.934	
		Liver	63.41 (5.88; 2)	51.25 (7.35; 2)	0.215	
		Muscle	65.48 (1.9; 2)	61.37 (6.16; 2)	0.512	
		Skin	59.1 (2.87; 2)	63.98 (1.8; 2)	0.202	

**Table S2**